CHRS: Don’t Miss Coherus’ Public Offering Opportunity!

Company Overview and Recent Developments

Coherus Oncology, Inc. (NASDAQ: CHRS), formerly Coherus BioSciences, is a U.S. biopharmaceutical company that has pivoted from a biosimilar drug business to focus exclusively on innovative cancer immunotherapies (investors.coherus.com) (investors.coherus.com). Coherus built its initial revenue base with biosimilars like Udenyca® (a Neulasta® biosimilar for chemotherapy patients) and Cimerli® (a Lucentis® biosimilar) (investors.coherus.com) (investors.coherus.com). In late 2024, Coherus announced the divestiture of its Udenyca franchise to Accord BioPharma (Intas Pharmaceuticals), a deal valued up to $558.4 million (with $483.4 million upfront) (investors.coherus.com). This strategic sale, along with earlier divestitures of Cimerli and the Yusimry™ Humira® biosimilar, marked Coherus’ transformation into an oncology-focused company built around its PD-1 immunotherapy, LOQTORZI® (toripalimab), and a pipeline of novel antibody drugs (investors.coherus.com) (investors.coherus.com). Management emphasized that these moves “dramatically” reduced debt while leaving roughly $250 million in cash on the balance sheet to fund development through 2026 (investors.coherus.com).

Most recently, in February 2026 Coherus conducted an underwritten public offering of common stock to bolster its finances. The company sold 28.6 million shares at $1.75 per share (with an option for ~4.29 million more), raising approximately $50.1 million in gross proceeds (www.globenewswire.com). Coherus intends to use the fresh capital to support the ongoing commercialization of LOQTORZI, advance clinical trials for its pipeline candidates, and for general corporate purposes (www.globenewswire.com). This equity raise provides additional runway to execute on upcoming clinical catalysts, and it gives investors a chance to invest alongside the company at what may be a pivotal time. Below, we dive into Coherus’ dividend policy, leverage and debt profile, financial valuation, and the key risks and open questions surrounding this opportunity.

Dividend Policy and Yield

Dividend History: Coherus is a growth-stage biopharma and has never paid a cash dividend on its stock (www.sec.gov). All available capital has been reinvested into product development, acquisitions, and commercialization rather than shareholder payouts. In fact, Coherus explicitly states it does not anticipate paying cash dividends in the foreseeable future, meaning investors should not expect any dividend income (www.sec.gov) (www.sec.gov). Even after the large asset sale windfalls, the Board confirmed it didn’t plan a special dividend from those proceeds (www.sec.gov), preferring to deploy funds into debt reduction and pipeline investment. As a result, CHRS’s dividend yield is 0%, and any investor returns will depend entirely on stock price appreciation rather than dividend distributions (www.sec.gov). This policy is typical for biotech companies in development mode – Coherus is prioritizing growth opportunities over near-term capital return.

Implications for Investors: The absence of dividends shifts the focus to capital gains potential. Investors in CHRS are effectively betting on the success of Coherus’ oncology franchise (LOQTORZI and pipeline) to drive the stock higher over time. It’s important to align this with one’s risk profile: Coherus’ strategy is high-risk/high-reward, and management has made it clear that shareholder value will come from pipeline execution, not from dividend income (www.sec.gov). Those seeking immediate yield may find CHRS unattractive, but those confident in the company’s clinical progress might view the disciplined reinvestment strategy favorably.

Leverage, Debt Maturities, and Coverage

Debt Profile Transformation: Coherus’ balance sheet has undergone a major cleanup in the past year. At the start of 2024, Coherus carried significant debt, including a $250 million term loan and $230 million of Convertible Senior Notes due April 2026 (www.fiercebiotech.com) (www.globenewswire.com). This leverage was a potential overhang. However, management used the proceeds from asset sales to aggressively pay down debt. In Q2 2024, Coherus prepaid $175 million of its term loan (originally from Pharmakon Advisors) and then fully paid off the remaining $250 million principal of that loan, slashing annual interest expense by ~70% (investors.coherus.com) (investors.coherus.com). Next, in early 2025 Coherus struck deals to retire practically all of its Convertible Notes: about $170 million of the notes were repurchased at par in a negotiated transaction (contingent on the Udenyca sale closing), with the remaining $60 million to be repaid after the sale via a mandatory repurchase offer (www.globenewswire.com) (www.globenewswire.com). Indeed, upon closing the Udenyca deal in April 2025, Coherus confirmed it had “dramatically” reduced its debt obligations (investors.coherus.com). The company also eliminated a $47.7 million royalty financing liability tied to Udenyca by buying out that revenue participation agreement using sale proceeds (www.fiercebiotech.com).

After these actions, Coherus’ only significant debt appears to be a relatively small $38.7 million term loan due 2029, which was entered in May 2024 (www.sec.gov). This 2029 loan carries interest of 8% + SOFR (floating) and is interest-only until maturity (www.sec.gov). With the convertible notes gone and royalty obligations settled, Coherus has no near-term major maturities to worry about. The remaining 2029 loan is modest in size and net debt is actually negative – the company holds far more cash than debt. In fact, as of April 2025 Coherus had about $250 million cash on hand post-UDENYCA sale, versus only ~$39 million in term debt (investors.coherus.com) (www.sec.gov). This implies a strong net cash position (over $200M net cash), which provides a significant cushion.

Interest Coverage and Cash Runway: With debt dramatically reduced, interest expense has fallen substantially. In 2023, Coherus’ interest expense was $40.5 million, but it dropped to $27.2 million for full-year 2024 after the term loan payoff (investors.coherus.com). Going forward, interest costs will decline further once the convertible notes’ 1.5% coupon is gone (that coupon was roughly $3.5 million annually on $230M principal). The remaining $38.7M loan might incur around ~$5–6 million of interest per year at current rates. Against a cash reserve in the hundreds of millions, Coherus can easily cover its interest for the foreseeable future. In other words, interest coverage is not a concern – the company’s cash on hand could pay years of interest expense, even though operating earnings are not yet covering those costs. Moreover, Coherus has projected its cash runway extends over two years (into 2027) (investors.coherus.com) (www.fiercebiotech.com), providing time to advance its drug pipeline. This projection assumed the $250M post-sale cash and the planned 30% reduction in headcount and expenses after divesting Udenyca (www.fiercebiotech.com) (www.fiercebiotech.com). The additional $50M equity raise in 2026 further bolsters the runway.

Overall Leverage Position: Coherus’ balance sheet appears well-fortified after the transformation. The company moved from a heavily leveraged position to a net cash position within a year – a rare positive for a small biotech. The reduced debt load not only saves interest costs but also frees Coherus from restrictive debt covenants. (Under its prior loan agreements, Coherus had various covenants to maintain cash levels and meet revenue benchmarks (www.sec.gov) (www.sec.gov); many of these encumbrances have been alleviated by debt paydowns and the shift to a leaner operation focused on oncology.) This healthier leverage profile lowers the financial risk for equity holders. It means the likelihood of distress or dilution driven by creditors is low in the near term, so long as Coherus manages its cash burn within the planned runway.

Valuation and Comparable Metrics

Market Capitalization and Financial Multiples: Coherus’ stock price has fallen substantially over the past few years as it underwent restructuring. As of mid-January 2026, CHRS traded around $1.60 per share, with roughly 116 million shares outstanding, for a market cap of only about $186 million (www.aaii.com). (Following the February 2026 offering, the share count will rise to ~145 million, putting the pro forma market cap near $250 million at the $1.75 offer price.) For context, Coherus’ trailing 2024 net revenue was $267.0 million (investors.coherus.com) – implying a price-to-sales (P/S) ratio under 1.0×. Even accounting for the fact that Coherus sold off a large portion of those revenue-generating assets (biosimilars), the company still has LOQTORZI and other income streams. On a forward basis, 2025 revenues will primarily come from LOQTORZI (which had $19.1M sales in 2024) (investors.coherus.com) and any collaboration or milestone payments. The market appears to be valuing Coherus at only a few times its remaining product sales, or arguably at less than the cash on its balance sheet when including the Udenyca sale proceeds. In April 2025, Coherus got $483 million upfront for Udenyca (investors.coherus.com) – over twice the entire company’s market cap in early 2026, underscoring how little value investors are currently ascribing to Coherus’ ongoing business and pipeline.

Traditional valuation metrics are somewhat quirky for Coherus due to one-time gains. Notably, Coherus actually reported GAAP net income of $28.5 million for 2024 (thanks to $176.6M in gain on asset sales) (investors.coherus.com) (investors.coherus.com). Using that one-off profit, the stock’s trailing P/E ratio looked extremely low (on the order of 3–6×) (www.aaii.com). However, this is misleading, since ongoing earnings are negative without those divestiture gains. In fact, on an operational basis Coherus remains unprofitable – its last-twelve-month operating income was roughly –$93 million (a –33% operating margin), reflecting heavy R&D and marketing investments relative to current revenues (www.trefis.com). Cash flow from operations is also deeply negative (–32% of sales over the LTM) (www.trefis.com). Therefore, a more meaningful way to think about valuation is enterprise value relative to assets and prospects: Enterprise Value (EV) is currently very low given the cash on hand. With ~$250M pro forma cash post-offering and a ~$250M market cap, Coherus’ EV is effectively near $0 – implying the market believes the pipeline’s risk-adjusted value is negligible. This seems overly pessimistic if one believes even one of Coherus’ drugs could reach market and generate substantial revenue. For example, LOQTORZI’s nasopharyngeal carcinoma indication is already generating revenue (albeit modest), and expansion into new indications could drive growth. Additionally, pipeline candidates like IL-27 antibody casdozokitug and CCR8-targeted CHS-114 address multi-billion dollar oncology markets (e.g. hepatocellular carcinoma, lung, head & neck cancers) (www.globenewswire.com) (www.globenewswire.com).

Comparative Landscape: As a micro-cap oncology player (~$200M market size), Coherus trades at a fraction of the valuation of larger immunotherapy companies, but investors should note that those peers often have at least one approved product with significant sales or later-stage pipelines. Coherus’ price-to-book (P/B) is likely near 1× or below, considering it held ~$250M in cash and investments against ~$580M total liabilities post-sale (much of which was convertible debt since repaid) (www.sec.gov) (www.sec.gov). The stock has been highly volatile, with a 52-week range roughly $0.71 – $1.89 (www.aaii.com). It surged in late 2025 on deal news (the stock more than doubled over 6 months) (www.trefis.com) (www.trefis.com), but pulled back to the ~$1–2 level. The low absolute share price could raise concerns about Nasdaq compliance if it were to fall below $1 (a risk to monitor, though currently it remains above that threshold). Overall, Coherus appears statistically “cheap” by many metrics (low EV/revenue, low P/B, etc.), but that is balanced by the high uncertainties surrounding its future earnings. The recent financing at $1.75 supports that there was institutional demand at that price – arguably a vote of confidence – yet it also dilutes existing shareholders by ~25%. Valuation upside would ultimately depend on successful drug development and revenue ramp in coming years, which the market is waiting to see.

Key Risks and Red Flags

Investing in Coherus is not without significant risks. Biotechnology Development Risk is front and center: Coherus is now heavily reliant on the unproven efficacy and commercial potential of its novel pipeline assets (www.trefis.com) (www.trefis.com). After divesting its stable biosimilar cash flows, the company’s future rides on drugs like casdozokitug (IL-27 antibody) and CHS-114 (CCR8 antibody) successfully completing clinical trials and demonstrating meaningful patient benefits. These programs are in Phase 1/2 studies – early-stage trials where failure rates are high across the industry. If Coherus’ much-touted candidates do not produce positive data in 2025–2026, the company will have little to show for its R&D spend and its stock could languish or worse. Moreover, regulatory risks remain: even with positive data, gaining FDA approvals for new cancer drugs is never guaranteed, and timelines can be long.

Commercial/Execution Risk is another concern. Coherus has one approved product, LOQTORZI (toripalimab), for a niche indication (nasopharyngeal carcinoma). While LOQTORZI is the first and only FDA-approved treatment for NPC and has “Preferred” status in NCCN guidelines (investors.coherus.com), the addressable U.S. patient population is relatively small. Coherus will need to expand toripalimab’s label or find new combination uses to significantly grow revenue (investors.coherus.com). However, competition in the PD-1/L1 immunotherapy space is intense – established giants like Merck’s Keytruda and Bristol Myers’ Opdivo dominate mainstream oncology indications. Coherus is attempting to carve out opportunities by combining LOQTORZI with its novel agents and in new settings, but there is a risk that physicians and payers stick with incumbent immunotherapies outside of NPC. Additionally, Coherus licenses toripalimab from Junshi Biosciences, meaning it likely owes royalties or profit-sharing on LOQTORZI sales (www.aaii.com). This could cap margins and makes Coherus dependent on its partner for supply and future indication development (any strategic or quality issues on Junshi’s side could impact Coherus).

Financial and Dilution Risk: While Coherus currently has a healthy cash cushion, it is not yet cash-flow generative – operating cash flow is deeply negative (www.trefis.com) (www.trefis.com) and the company continues to post net losses excluding one-time gains (www.trefis.com). If the pipeline advancement takes longer or costs more than anticipated, Coherus might need additional financing down the line. Equity dilution is a real possibility (the recent offering itself dilutes existing holders by ~24%). Notably, short interest in CHRS has been high – roughly 26% of float was sold short, with about 18 days of average volume needed to cover (www.trefis.com) (www.trefis.com). This indicates some investors are betting on the stock’s decline, possibly anticipating further dilution or setbacks. A high short position can add to stock volatility and downside pressure, though it also raises the scenario of a short squeeze if positive news surprises the market.

Another red flag is execution on the new strategy. Coherus effectively overhauled its business in a short time: divesting three product lines (biosimilars for ophthalmology and immunology), cutting 30% of staff, and shifting focus to oncology R&D (www.fiercebiotech.com) (www.fiercebiotech.com). Such transitions are challenging. Management will need to prove that they can operate efficiently as a smaller, research-oriented company and successfully market LOQTORZI without distraction. The track record is mixed – Coherus did well with biosimilar launches historically, but innovator drug marketing is a different arena. Any stumbles in the LOQTORZI launch or delays in clinical programs could erode investor confidence. Also, milestone dependency is a minor risk: Coherus is eligible for up to $75M in milestone payments from Intas/Accord if Udenyca sales hit certain thresholds (investors.coherus.com). If those milestones aren’t met (for instance, due to competition in the biosimilar Neulasta market), Coherus would miss out on that extra non-dilutive funding.

Lastly, one should consider macroeconomic and market conditions. The biotech sector can be highly sensitive to capital market conditions; a downturn could make funding more costly and pressure small-cap biotech valuations. Coherus is not immune to broader market sentiment – its share price has been beaten down over the past 2–3 years (www.trefis.com), and investor appetite for high-risk biotech has been fickle. Until Coherus delivers clear clinical wins or revenue growth, the stock could remain under pressure or trade range-bound, so patience is required.

Open Questions and What to Watch

Despite the risks, Coherus’ recent moves also create some intriguing open questions and potential catalysts for investors considering this offering opportunity:

- Can LOQTORZI Achieve Broader Commercial Success? As of 2024, LOQTORZI’s sales were modest ($19.1M in its launch year) (investors.coherus.com). Coherus is focusing on maximizing LOQTORZI in NPC and pursuing label expansions via combination trials (investors.coherus.com). Upcoming data will be critical – for example, how will LOQTORZI perform in head and neck cancer or other solid tumors when combined with CHS-114 or casdozokitug? Early signs like NCCN guideline inclusion are promising (investors.coherus.com), but the true test will be uptake and reimbursement. Investors should watch quarterly LOQTORZI revenue trends and any new partnerships Coherus forms to promote toripalimab in additional indications. Success in growing LOQTORZI sales could validate Coherus’ commercial capabilities and provide much-needed cash flow.

- Pipeline Clinical Readouts: The next 12–18 months will bring multiple data readouts from Coherus’ innovative pipeline. For instance, Phase 2 results in 1st-line liver cancer (HCC) combining casdozokitug with toripalimab and bevacizumab are expected in 2025 (investors.coherus.com). Phase 1 combo data for CHS-114 in head & neck cancer is expected in the first half of 2025, with more in 2026 (investors.coherus.com). These readouts are high-stakes events. Positive efficacy signals (e.g. tumor response rates, progression-free survival improvements) could quickly shift the market’s perception of Coherus, opening doors to potential partnerships or licensing deals with larger pharma companies. On the other hand, disappointing results would raise questions about the value of these programs. Each trial outcome will answer the question: Is Coherus’ pipeline science translating to clinical benefit? Investors should keep a close eye on conference presentations (ASCO, ESMO, etc.) and press releases around these studies.

- Use of Proceeds and Cash Burn: With an extra $50M from the latest offering, how exactly will Coherus allocate capital? The stated use is to fund LOQTORZI’s ongoing commercialization and pipeline development (www.globenewswire.com). An open question is whether this cash is earmarked for specific new trials or perhaps to push one asset faster (for example, advancing CHS-1000 – their preclinical ILT4 antibody – into the clinic). Also, will the company’s burn rate remain in check? Coherus slimmed down its operations post-divestitures (targeting ~155 employees and lower SG&A) (www.fiercebiotech.com), but R&D expenses will ramp as trials progress. Monitoring quarterly cash flow and operating expense levels will indicate if Coherus is pacing its spend to match its “>2 year” runway guidance. If the burn unexpectedly accelerates, that could foreshadow a need for further fundraising – conversely, disciplined spending would de-risk the financing aspect. Essentially, can Coherus reach its 2026 data catalysts without needing more cash? – that’s a question investors will be asking. So far, with ~$300M total pro forma cash (post-sale and offering), it appears feasible, but it warrants monitoring.

- Strategic Moves – Partnerships or M&A: Now that Coherus has refocused, will management consider strategic partnerships to unlock value? For example, they might partner a pipeline asset (or regional rights for LOQTORZI) to a bigger pharma for an upfront payment. Coherus has a collaboration history (e.g. Junshi for toripalimab, prior deals for biosimilars) (www.aaii.com). Given the breadth of its pipeline for a small company, partnering could be wise to share costs. Any deal could provide non-dilutive capital and validation. Another open question: might Coherus itself become a takeover target? With a depressed valuation and a U.S.-approved PD-1 drug on the market, Coherus could be attractive to a larger biotech looking for an approved asset plus pipeline. There are precedents of small immunotherapy companies being acquired if their assets show promise. While nothing concrete has been stated, investors may speculate on this as data emerges.

- Milestone from Intas/Accord: Coherus is due up to $75 million in milestones if Accord (INTAS) achieves certain Udenyca sales levels (investors.coherus.com). It’s worth questioning how achievable those are. If Udenyca maintains market share or expands (perhaps via the OnBody injector format for Neulasta), Coherus could receive part or all of that $75M over time. Those payments would further extend its cash runway. Clarity on the milestone timeline or probability (which management might give in earnings calls) is something to watch. It’s essentially an “extra” that’s not counted in guidance but could provide upside surprise.

In summary, Coherus has navigated a dramatic transition – shedding its legacy products, shoring up the balance sheet, and doubling down on oncology innovation. The recent public offering gives investors a timely entry point as the company enters a catalyst-rich period. However, this opportunity comes with high volatility and risk typical of clinical-stage biotech. Success is far from guaranteed, but if Coherus’ management executes and the science delivers, the rewards could be substantial. Conversely, setbacks in trials or slow uptake of LOQTORZI would likely keep pressure on the stock. Investors should weigh the strengthened financial position and low valuation against the potent risks of drug development. As always, diversifying risk and sizing any position appropriately is prudent. Coherus’ story over the next two years will answer the open questions – and those outcomes will determine whether this offering was a springboard to long-term gains or a value trap. For now, Coherus offers a compelling, if speculative, opportunity to bet on a revitalized cancer therapeutics player with cash in hand and multiple shots on goal. The coming quarters will be critical in showing whether that bet pays off.

Sources: Coherus investor presentations, SEC filings, and press releases; industry news coverage and financial data as cited. The information above incorporates data from Coherus’ 10-K and earnings releases, transaction announcements, and third-party analysis to ensure a factual, up-to-date assessment of CHRS (investors.coherus.com) (investors.coherus.com) (www.fiercebiotech.com) (www.trefis.com), among other cited references throughout the report.